标题: IBI3001,一种潜在全球首创(First-in-Class)的糖基化定点偶联 B7-H3/EGFR 双抗ADC 在多项临床前实体瘤模型中的表现摘要号:LB055展示形式:壁报时间:2024年4月7日(星期日) 1:30 PM – 5:00 PM (当地时间)地点:Poster Section 53讲者:何开杰博士IBI3001是一款潜在全球首创针对B7-H3和EGFR...
本次会议上由山东第一医科大学附属肿瘤医院赵磊教授开展的“Camrelizumab combined with apatinib and hepatic artery infusion chemotherapy (HAIC) as conversion therapy forpatients with unresectable hepatocellular carcinoma(HCC): a single-arm exploratory clinical study”入选本次大会Poster1。研究结果显示,卡瑞利...
时间:2024年4月7日(星期日) 1:30 PM – 5:00 PM (当地时间) 地点:Poster Section 53 讲者:何开杰博士 IBI3001是一款潜在全球首创针对B7-H3和EGFR的双特异性ADC,采用经临床验证的SYNtecanE®定点偶联平台。 IBI3001具有多重抗肿瘤的机制:(1)增强的EGFR信号阻断;(2)EGFR与B7-H3介导的药物内吞与细胞杀伤;...
编者按:2024年第115届美国癌症研究协会(AACR)年会将于4月5日~10日在美国圣地亚哥举行,今年大会的主题是“激励科学·推动进步·革新诊疗(Inspiring Science·Fueling Progress·Revolutionizing Care)”。本文整理出大会已公布的肺癌领域中国讲者的最新研究,以飨读者。 01 Late-Breaking Poster Session 摘要号:LB266...
Late-Breaking and Clinical Trials Abstract Withdrawal Deadline:February 23, 2024 - LBA和临床试验摘要撤回截止日期 Abstract Submission Deadline: Undergraduate Student Caucus and Poster Competition:February 29, 2024 Regular Abstract Titles and Texts Posted to Online Itinerary Planner: March 5, 2024(4:30...
Late-Breaking and Clinical Trials Abstract Withdrawal Deadline:February 23, 2024 - LBA和临床试验摘要撤回截止日期 Abstract Submission Deadline: Undergraduate Student Caucus and Poster Competition:February 29, 2024 Regular Abstract Titles and Texts Posted to Online Itinerary Planner: March 5, 2024(4:30...
Late-Breaking Poster Session 摘要号:LB266 / 11 英文标题:AMG510-mediated inactivation of BCL-xL protein promotes Gasdermin-E-dependent pyroptosis in KRAS-G12C mutant non-small cell lung cancer 中文标题:AMG510介导的BCL-xL蛋白失活促进KRAS-G12C突变...
IBI343,一种定点偶联抗Claudin18.2 ADC用于治疗实体瘤,临床前发现及特征摘要号:LB057展示形式:壁报时间:2024年4月7日(星期日) 1:30 PM – 5:00 PM (当地时间)地点:Poster Section 53讲者:何开杰博士壁报展示会议类别:免疫学-单抗和双抗 标题:兼具高效抗肿瘤活性和可接受安全性的新型 TROP2 靶向免疫刺激抗体...
Clinical Trials Poster Session CT053 / 3 - Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plustislelizumab(anti-PD-1) in 1L PD-L1+ non-small cell lung cancer (NSCLC) • H. Kim,Yonsei Cancer Center, Severance Hospital, Yonsei University College of...
(serplulimab) as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) was published as poster presentation at the American Association for Cancer Research 2024 meeting (AACR 2024), with Professor Ying Cheng from Jilin Province Cancer Hospital as the leading ...